The Association of Elevated 2′,5′-Oligoadenylate-Dependent RNase L with Lung Cancer Correlated with Deficient Enzymatic Activity and Decreased Capacity of RNase L Dimerization by Yin, Huijing et al.
Cleveland State University
EngagedScholarship@CSU
Chemistry Faculty Publications Chemistry Department
10-1-2012
The Association of Elevated 2′,5′-Oligoadenylate-
Dependent RNase L with Lung Cancer Correlated
with Deficient Enzymatic Activity and Decreased
Capacity of RNase L Dimerization
Huijing Yin
Tongji University School of Medicine
Aimin Zhou
Cleveland State University, A.ZHOU@csuohio.edu
Yalei Dai
Tongji University School of Medicine
Follow this and additional works at: https://engagedscholarship.csuohio.edu/scichem_facpub
Part of the Chemistry Commons
How does access to this work benefit you? Let us know!
This Article is brought to you for free and open access by the Chemistry Department at EngagedScholarship@CSU. It has been accepted for inclusion
in Chemistry Faculty Publications by an authorized administrator of EngagedScholarship@CSU. For more information, please contact
library.es@csuohio.edu.
Recommended Citation
Yin, Huijing; Zhou, Aimin; and Dai, Yalei, "The Association of Elevated 2′,5′-Oligoadenylate-Dependent RNase L with Lung Cancer
Correlated with Deficient Enzymatic Activity and Decreased Capacity of RNase L Dimerization" (2012). Chemistry Faculty
Publications. 421.
https://engagedscholarship.csuohio.edu/scichem_facpub/421
The association of elevated 2′,5′-oligoadenylate-dependent RNase L with lung
cancer correlated with deﬁcient enzymatic activity and decreased capacity of
RNase L dimerization
Huijing Yin , Aimin Zhou , Yalei Dai
Introduction
Lung cancer is the most common cause of cancer deaths in the
world with over one million new cases diagnosed per year [1].
The etiology of lung cancer has been shown to be multifactorial,
including genetic, epigenetic, and environmental factors such as
tobacco smoking. Although smoking remains the most important
etiological factor which associated with more of 90% of cases of
lung cancer [2], accumulating evidence has showed that genetic
factors may modify the risk of lung cancer. There is a clear role for
genetics since only 15% of lifetime smokers develop lung cancer
and 10% of lung cancers occur in never-smokers especially in
women [3] and in Asiatic women in particular [4]. Thus, a growing
body of evidence has shown the role of genetic background
in lung cancer susceptibility, progression, and prognosis [5–8].
Genetics studies support the RNase L gene as a strong candidate
for hereditary prostate cancer 1 (HPC1) allele [9,10]. Increasing
genetic and functional studies have revealed a strong association
between defects in endoribonuclease L (RNase L) activity owing
to mutation or dysfunction and increased risk of cancer such as
prostate cancer [11,12] and colorectal cancer [13,14].
RNase L functions in the 2′,5′-linked oligoadenylates (2-5A)
system of interferon (IFN) action against viral infection and cell
proliferation. The 2-5A system mediates host defense against cer-
tain types of viral infections. Cells overexpressing RNase L can
overcome viral infection [15]. In contrast, overexpression of a
dominant negative mutant of RNase L results in increased suscep-
tibility to viral infection [16]. In vivo studies showed that mice
containing targeted disruption of RNase L gene succumbed to
encephalomyocarditis infection more rapidly than infected wild
type mice [17,18]. The mechanism of RNase L acting as a candidate
of tumor suppressor is thought to involve the selective regulation
of mRNAs encoding proliferation-stimulatory or cytostatasis/cell
death-inhibitory proteins. The different RNA substrates of RNase L
have been identiﬁed such as IFNor PKR [19,20]. It has been reported
that alphavirus-based DNA vaccine against a non-mutated tumor-
associated self-antigen (tyrosinase-related protein-1, TRP-1) was
severely impaired in RNase L null mice, indicating that RNase L
has functions in host immune system against cancer [21]. RNase
L activity is modulated by a member of the ATP-binding cassette
(ABC) transporter protein, such as RNase L inhibitor (RLI)-HP68,
now classiﬁed as ABCE1 protein [22]. Interestingly, the expression
levels of ABCE1 mRNA and protein were elevated in lung adenocar-
cinoma tissues [23]. A clinical study showed that the level of RNase
in serum was signiﬁcantly higher in patients with lung carcinoma
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Fig. 1. Immunocytochmical staining of RNase L in different types of cells. The expression patterns of RNase L in the studied cells were stained by indirect immunocytochemistry
with a speciﬁc mouse against human RNase L IgG-mAb. (A) Immunolocalized intracellular RNase L appeared as reddish-brown after DAB staining. (a) A strong brown staining
was  observed in all three types of lung cancer cells and normal lung cell BEAS-2B. A weak brown staining was observed in the four types of breast cancer cells. (b) The most
brown staining areas were distributed around the nuclei after counterstained with Mayer’s Hematoxylin. (c) IgG1 served as a mock staining for these cells. Bar = 50 M (400×
magniﬁcation). (B) The expression levels of intracellular RNase L in the different cell groups were presented with the intensity of staining grade analyzed by ImageJ (National
Institutes of Health, USA). The data were from three independent experiments and presented as mean ± S.D. *** indicates P < 0.001 between two groups.
compared with healthy nonsmokers [24] although which category
of RNase was increased is unclear. The physiological signiﬁcance of
the observations in lung cancer remains largely unknown.
In  the present work, we determined the differential expres-
sion of RNase L in various cell types and found that RNase L is
highly expressed in lung cancer cells with signiﬁcantly decreased
enzymatic activity due to an increase of RLI. Our ﬁndings provide
a further understanding of how lung cancer cells escape growth
regulating mechanisms to form a tumor.
Materials  and methods
Cells  culture and transfection
The  human cell lines used in this study were purchased from the
Shanghai Institute of Cell Biology (China) including lung adenocar-
cinoma cell lines (A549, NCI-H460 and SPCA-1), breast carcinoma
cell lines (MDA-MB-231, T47D, MDA-MB-453 and MCF-7), and nor-
mal  lung cell line BEAS-2B and blood monocyte cell line THP-1.
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Fig. 2. Expression levels of RNase L mRNA in different types of cells. The RNase L mRNA expression pattern was explored in the studied cells by real-time quantitative PCR.
(A)  Ampliﬁcation curves represent the cycle-dependent ﬂuorescent kinetic proﬁles associated with the ampliﬁcated cDNAs of RNase L gene (left) and internal control -actin
gene  (right) in the same samples, respectively. (B) A typical melting curves (heat dissociation) of PCR products for both RNase L and -actin genes yielded a single peak at
92.8 ◦C (left) and 83.9 ◦C (right) respectively. (C) A representative standard curve measurements for RNase L and -actin genes were constructed (left) and a representative
ampliﬁcation efﬁciency was demonstrated as a slope (right). (D) The relative RNase L mRNA expression levels in different cells were represented as the fold change compared
with  that in BEAS-2B cell. All data were shown as mean ± S.D. from three independent experiments. *, ** and *** indicate P < 0.05, P < 0.01 and P < 0.001 respectively compared
with BEAS-2B cell.
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The cells were grown in RPMI 1640 medium or DMEM contain-
ing 10% FBS (Gibco). Cell transfection with pEGFP-N3 recombinant
plasmid containing wild-type RNase L was carried out by using lipo-
fectAMINE reagent (Invitrogen) according to the manufacturer’s
instruction.
Immunocytochemistry staining
An Avidin-Biotin-Peroxidase Complex (ABC) method was  used
to localize/visualize the protein expression of RNase L in the cells.
Cells were incubated with the mouse anti-human RNase L antibody
(from Dr. Zhou Lab), before incubation with biotinylated goat anti-
mouse IgG, and followed by incubation with streptavidin–avidin
horseradish peroxidase (HRP). DAB substrate was  used for develop-
ing brown reaction products and Mayer’s Hematoxylin was used to
counterstain nuclear. Mouse anti-human IgG1 served as a negative
control. The cells images were obtained under a light microscope
(Motic, BA300, Germany).
Quantitative real-time PCR
Total RNAs from the cells were isolated using Trizol
reagent (Invitrogen). RNA reverse transcription was  carried
out by using ImProm-IITM reverse transcription kit (Promega)
according to the manufacturer’s instruction. The cDNA was
subsequently analyzed in the qPCR run on the Corbett
Rotor-Gene 3000 (Corbett Research) by using SYBR® Pre-
mix Ex TaqTM II kit (Takara) and the real-time PCR primers
designed as follows: 5′-CTTAAGGCCCAGGACTGTGGAG-3′ and
5′-TCCATCACTACAGATCCAGCAAGAG-3′ for RNase L
(NM 021133); 5′-CCAAGCGCCTATGGAGTTGTC-3′ and 5′-TCATTT-
GCTGTCTCAGCCACTTTA-3′ for RLI (NM 001040876.1), and
5′-ATTGCCGACAGGATGCAGA-3′ and 5′-GAGTACTTGCGCTCAGGA-
GGA-3′ for -actin (NM 001101.3). The absence of primer-dimer
formation for each oligonucleotide set was validated by estab-
lishing the melting curve proﬁle. The gene expression levels were
calculated by CT  method.
Western  blotting
The  equal amounts of proteins were separated using 12% SDS-
PAGE electrophoresis and electransferred onto PVDF membrane.
The membranes were blocked with 5% milk before incubation with
mouse anti-human RNase L and RLI antibodies (ProSci) for detec-
tion RNase L and RLI respectively. The blots were developed with
ECL system and exposed to X-ray ﬁlm (Eastman Kodak) after incu-
bation with goat anti-mouse horseradish peroxidase-conjugated
secondary antibody (Jackson). The internal control for normaliz-
ing the protein, -actin, was detected by incubation with mouse
anti--actin antibody followed by goat anti-mouse horseradish
peroxidase-conjugated secondary antibody.
2-5A synthesis and treatment
2-5A [p3(A2′p)nA, where n = 1 to ≥3] was prepared enzy-
matically from ATP by using recombinant 2′,5′-oligoadenylate
synthetase 1(40/46 kDa) (Abnova). Brieﬂy, reaction mixture includ-
ing OAS1 buffer [20 mM HEPES (pH 7.6), 20 mM magnesium acetate,
20 mM  KCl and 1 mM EDTA], 20 g/ml human full-length recombi-
nant protein OAS1, 10 mM ATP (pH 7.4) (Cell Signaling Technology)
and 1 g/ml poly (I:C) (InvivoGen), was incubated at 37 ◦C for 24 h.
The synthesized 2-5A was harvested by centrifugation at 3,000 g for
15 min  through a Centricon-10 ﬁlter (Millipore Corp.) to separate
from reaction mixture. The freshly synthesized 2-5A was  diluted
into 100 nM with Opti-MEM medium (Invitrogen) and mixed with
Fig. 3. Expression levels of RNase L protein in different types of cells. The expression
protein  levels of RNase L were detected in the studied cells by western blotting with
a speciﬁc mouse against human RNase L IgG-mAb. A typical expression pattern of
RNase L protein levels was shown by western blotting. The protein level of -actin
served  as the internal control. The relative RNase L protein expression levels in the
different cells were presented as the fold change compared with that in BEAS-2B
cell.  The data were shown as mean ± S.D. from three independent experiments. *, **
and *** indicate P < 0.05, P < 0.01 and P < 0.001 respectively compared with BEAS-2B
cell.
calcium phosphate for 20 min, then applied to the cells for the indi-
cated time for RNase L functional study.
Detection of RNase L activity
Total RNA was  isolated from the cells using Trizol reagent fol-
lowed by chloroform extraction and isopropanol precipitation.
After washed with 70% ethanol, the RNA was  dissolved in Tris–HCl
(pH 7.5) buffer containing 5 mM MgCl2 and 0.1 mM CsCl. The ribo-
somal peak areas of 28S and 18S rRNA and cleavage products were
visualized under UV light after staining with ethidium bromide.
RNase L activity was  determined by measuring the percentage of
rRNA cleavage products [25].
RNase  L dimerization assay
After incubation, cells were treated with cocktails-mixture of
protease and phosphatase inhibitors for 10 min before lysed in ice-
cold non-denaturing lysis buffer [20 mM Tris–HCl pH 8.0, 137 mM
NaCl, 10% glycerol, 1% NP-40, 2 mM EDTA]. The protein pellets were
incubated with 5 mg/ml  dimethyl suberimidate (Fluka) for 30 min
and immediately terminated with loading buffer before boiled at
for 5 min  to denature the protein. Then proteins were separated by
8% SDS-PAGE and applied to western blot analysis.
Statistical analysis
All  experiments were repeated at least three times. Data were
expressed as the mean ± S.D. and statistical analyses between
groups were performed using a one-way ANOVA, followed by the
paired Student’s t-test. The differences were considered statisti-
cally signiﬁcant when P < 0.05.
033
Fig. 4. Monitoring RNase L-mediated rRNA cleavage in different types of cells. RNase L activities were determined in the studied cells (A) Time course of 2-5A-induced rRNA
cleavage was carried out in order to optimize reaction time. BEAS-2B cells were treated with or without 2-5A for the indicated time periods before extracting total RNA. The
percentage of cleavage rRNA was  determined and indicated. The data were shown as mean ± S.D. from three independent experiments. (B) The total RNA were extracted
from BEAS-2B, A549, NCI-H460, SPCA-1 cells and these cells transient transfected with wild-type of RNase L after incubating with or without 2-5A for 24 h. The speciﬁc 28S
rRNA  cleavage fragments were quantiﬁed and calculated by the densitometry of 28S rRNA cleavage fragments over total 28S rRNA. The percentage of 28S rRNA cleavage was
presented  as mean ± S.D. from three independent experiments. ** indicates P < 0.01 compared with BEAS-2B cell. ♦♦ indicates P < 0.01 compared between two groups. (C)
Extracted  proteins from BEAS-2B, A549, NCI-H460, SPCA-1 cells and those cells transient transfected with pEGFP-N3–RNase L (wild-type) recombinant plasmid were probed
with  the antibody for RNase L. The arrows indicated the positions of native RNase L and pEGFP-N3–RNase L fusion proteins respectively. The expression levels of RNase L
and  pEGFP-N3–RNase L were presented as the ratios of RNase L (open bars) or pEGFP-N3–RNase L (hatched bars) over -actin, respectively. The mean ± S.D. was  calculated
from three independent experiments. ♦♦♦ indicates P < 0.001 compared with its untransfected cell. (D) The effect of poly (I:C)-induced rRNA cleavage was performed in
order  to compare with 2-5A-induction. Total RNAs were extracted from BEAS-2B, NCI-H460 and SPCA-1cells after incubating with or without poly (I:C) for 24 h. The cleavage
products of rRNA were observed and indicated.
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Fig. 5. Comparison of RNase L homodimer formation in different types of cells. Total proteins were extracted from BEAS-2B, A549, NCI-H460 and SPCA-1 cells after incubating
with or without 2-5A for 24 h. Then the proteins were incubated with DMS  to covalently cross-link homodimers of RNase L before separating on the 8% SDS-PAGEs. The
immobilized monomer and dimer of RNase L were detected in western blots by probing with speciﬁc antibody to human RNase L, as indicated with arrows. The quantity
of the monomer and dimer of RNase L was determined by the densitometry of RNase L band normalized to the amount of internal control -actin. The data were shown
as mean ± S.D. from three independent experiments. *** indicates P < 0.001 compared with BEAS-2B cell for the dimer and monomer of RNase L respectively. ♦♦♦ indicates
P  < 0.001 between the two group.
Results
To determine the expression of RNase L in lung cancer cells, we
performed immunocytochemical staining to examine the RNase L
protein levels in several types of lung cancer cells in compared
to that in breast cancer cells and normal lung cells. As shown
in Fig. 1A, a strong positive staining was observed in the three
types of lung cancer cells (Fig. 1A(a)), which were apparently dis-
tributed around nuclei of the cells (Fig. 1A(b)). In contrast, RNase L
was much less expressed in breast cancer cells and normal lung
cells examined. The average level of RNase L expression in the
lung cancer cells (13.9 × 105 RU/cell) was about 4.3- and 17.3-fold
of that in normal lung cells (3.2 × 105 RU/cell) and breast cancer
cells (0.8 × 105 RU/cell) respectively (Fig. 1B). Further to determine
at which level of RNase L is up-regulated, the RNase L expres-
sion in mRNA and protein levels were examined by using qPCR
and western blot analysis. The mRNA and protein levels of RNase
L were increased to 3.44- and 11.4-fold in A549 cells, 2.94- and
8.9-fold in NCI-H460 cells, and 3.94- and 12.2-fold in SPCA-1 cells
respectively compared with that in the corresponding normal lung
cells (Figs. 2 and 3). Whereas in the breast carcinoma cells, the
expression levels of RNase L mRNA and protein were remained low
which were consistent with immunocytochemical staining results
(Fig. 1A). The up-regulated RNase L mRNA expression pattern was
also found in other types of lung cancer cells, such as NCI-H157,
GLC-82, Calu-3, LTEP-s, NCI-H520, NCI-H209 and PG-LH7 (data not
shown). These results were consistent with previous observation
that RNase L is found to be highly expressed in some types of cancer
cells  such as prostate cancer [11,12] and colorectal cancer [13,14].
The physiological signiﬁcance of the aberrant expression of RNase L
in cancer cells remains unknown although the expression of RNase
L in the lung cancer cells is up-regulated at both transcriptional and
translational levels (Figs. 2 and 3).
It have been reported that an increased expression of RNase L
may be associated with the RNASE L gene mutation in prostate
cancer cells [12,26]. However, we have not found any mutation
in RNASE L gene that cloned from the lung cancer cells (A549,
NCI-H460 and SPCA-1) by using the nest PCR technique (data not
shown). We  next examined RNase L enzymatic activity by mea-
suring rRNA cleavage in these cells induced by 2-5A (Fig. 4). The
time course shows that the maximal 28S rRNA cleavage appeared
at 24 h in BESA-2B cells after treatment with 2-5A (Fig. 4A). Inter-
estingly, the percentages of 28S rRNA cleavage in the cancer cells
treated with 2-5A under the same condition were signiﬁcantly
reduced compared with that in BESA-2B cells (Fig. 4B, open bars)
although the RNase L protein levels in the cancer cells were signif-
icantly higher (Fig. 3). In order to examine the effects of aberrantly
expressed RNase L in the lung cancer cells, the pEGFP-N3-RNASE
L (wild-type) plasmid was constructed and transfected into the
cancer cells and BESA-2B cells. As shown in Fig. 4C, the expres-
sion of pEGFP-N3-RNase L was ectopically increased about 3-fold in
BESA-2B cells as well as in the three types of lung cancer cells. Sur-
prisingly, the RNase L activity in transfected lung cancer cells barely
changed after the cells were induced with 2-5A for 24 h (Fig. 4B,
hatched bars). However, the increased level of RNase L activity
in BESA-2B cells was consistent with the increase of the RNase L
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protein after the cells were transfected with the construct. Inter-
estingly, the rRNAs cleavage patterns in the cancer cells induced by
poly(I:C) were different from that by 2-5A (Fig. 4D). Taken together,
our data suggest that there may  be an inhibitor which is able to
inhibit RNase L activation in lung cancer cells.
Since dimerization of RNase L induced by 2-5A is an indis-
pensable step for its enzyme activation to cleavage rRNA [27], we
examined whether high expressed RNase L in the lung cancer cells
is able to form a dimer in response to 2-5A binding. It is surpris-
ing the ability of RNase L dimerization in these lung cancer cells
was remarkably reduced in comparison with that in BESA-2B cells
(Fig. 5). The results distinctly implicate that the dysfunction in
RNase L activity was due to that RNase L was unable to form a dimer
in these lung cancer cells. It has been well established that RNase
L activity can be regulated by RLI, a speciﬁc inhibitor of RNase L.
RLI functions as a regulatory protein to inhibit RNase L molecule
interaction from forming a dimer, resulting in a reduction of RNase
L activation for cleaving rRNA induced by 2-5A [22]. To determine
whether 2-5A induces RLI synthesis, the expression of RLI in these
lung cancer cells and normal lung cells were examined. Interest-
ingly, the expression of RLI in the lung cancer cells was  signiﬁcantly
higher than that in normal lung cells after incubation with 2-5A.
Quantitative analysis revealed that the both levels of RLI mRNA and
protein were signiﬁcant increased in the lung cancer cells compared
with that in BEAS-2B cell (Fig. 6). More interestingly, the level of
RLI was signiﬁcantly reduced in BEAS-2B cells after induced with
2-5A while the reverse results were observed in the cancer cells.
The results suggest that the dysfunctional activity of RNase L in
lung cancer cells may  be caused by aberrantly expressed RLI that
interrupts dimerization of RNase L.
Discussion
It has been well established that RNase L plays an important
role in regulating cellular senescence, cellular proliferation, and
cell survival. Aberrant expression of RNase L can either promote
cell death or result in enhanced susceptibility to microbial infec-
tions and cancer [28,29]. Emerging evidence suggests that RNase
L expression in cancer cell may  represent an important prognos-
tic marker to predict disease outcome for cancer patients. In this
study, we have presented evidence showing that although RNase L
is highly expressed in lung cancer cells, RNase L cannot be activated
as a result of failure of dimerization caused by up-regulation of RLI
expression. Our ﬁnding provides new insight into how cancer cells
escape the antiproliferative mechanism in the host to form a tumor,
which may  be useful for the design of novel strategies for treating
lung cancer through regulating RNase L activity.
RNase L is associated with an increased risk of carcinoma of
the uterine cervix, and carcinomas of head and neck squamous cell
reveal a strong association between defects in RNase L activity and
tumorigenesis [30]. To elucidate the potential role of RNase L in
lung carcinomas, we examined its expression pattern and function
in the A549, NCI-H460 and SPCA-1 lung cancer cells. As expected,
the RNase L activities in the lung carcinomas cells were deﬁcient.
Interestingly, the lack of RNase L activity was not correlated with
gene mutations but attributed to a reduction of RNase L dimeriza-
tion as a catalytically active form. To date, the reason for the defect
of RNase L in cancer is supported by the identiﬁcation of different
mutations (M1I, E265X, 471 AAAG, and R462Q) with disease onset
and/or frequency [10,11]. However, our results have found a rare
phenomenon that there was no obvious gene alteration accounted
for RNase L defect, which may  offer a new cause to the inactivation
of RNase L in cancer.
To  further explore the correlation between the expression and
function of RNase L, overexpression of wild-type of full-length
Fig. 6. Expression of RLI mRNA and protein levels in different types of cells. RLI
levels  were detected in BEAS-2B, A549, NCI-H460, and SPCA-1 cells after incubating
with  or without 2-5A for 24 h. (A) The RLI mRNA expression pattern was explored by
real-time quantitative PCR. The transcript amount of RLI mRNA was normalized with
-actin mRNA. The levels of relative RLI mRNA expression in the cells were repre-
sented  as the fold change compared with untreated BEAS-2B cell. (B) The expression
protein  levels of RLI in the same samples were detected by western blotting with RLI
antibody and normalized to the amount of -actin presented. The relative RLI pro-
tein expression levels in the cells after treating with or without 2-5A were calculated
by  the fold change compared with untreated BEAS-2B cell. All data were shown as
mean ± S.D. from three independent experiments. *** indicates P < 0.001 compared
with  untreated BEAS-2B cell. ♦♦♦ indicates P < 0.001 between two groups.
RNASE L in the lung cancer cells were studied. Unexpectedly,
RNase L cleavage activity was  reduced in the cancer cells expressed
higher levels of RNase L. The results suggested the correlation
between the function of RNase L and the expression level of RNase
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L was inversely related. The absence of mutations suggests that the
decreased activity may  be involved in the protection mechanism
of lung cancer cells against RNase L activity, which may  promote
cancer cell growth. RLI can form a heterodimer with RNase L and
inhibit the binding of 2-5A by RNase L in a noncompetitive manner
[22]. Some viruses could recruit a host protein to inhibit RNase L
activity, which is the case for EMCV and HIV-1 that lead to increased
expression of RLI [31,32]. Our results also demonstrated that RNase
L cannot be activated as a result of failure of dimerization caused
by the upregulation of RLI expression.
Interestingly, different cancer cells may  escape the growing-
regulatory mechanism to form a tumor through their unique
strategy. For example, the etiology of hereditary prostate can-
cer has been found to be correlated with the RNase L gene
mutation. Functional analysis or epidemiologic study of the role
of RNASEL in hereditary prostate cancer has been observed in
most, but not all, studies [9,10]. The R462Q variant of RNase
L, which has an attenuated enzymatic activity, is found in up
to 13% of prostate cancer cases [33]. Individuals heterozygous
for these mutations exhibit a 150% increased risk of prostate
cancer, and homozygotes have greater than double of the risk,
underscoring the importance of inactivating RNase L in the devel-
opment of this disease [34]. RNase L is also found to be highly
expressed in colon cancer tissues compared with that in their
paired normal tissues. Although puriﬁed RNase L from colorec-
tal tumor tissues by using 2-5A afﬁnity resin is functional, it
is possible that non-covalent binding inhibitors of RNase L may
have been removed during the puriﬁcation process [14]. In addi-
tion, it has been reported that there is an RNase L inhibitor
binding with RNase L to prevent the turnover of mRNA-protein
(mRNP) by RNase L in the cytoplasm of human placenta [35].
Collectively, these observations implicate that RNase L, a grow-
ing regulator, may  be inhibited by distinct inhibitors in different
microenvironment.
Conclusion
Tumor formation is a net outcome of the balance of suppres-
sion and proliferation in cancer cells. Cancer cells must suppress
all growing-regulatory mechanisms including RNase L in order to
form a tumor although the molecular basis underlying the phe-
nomena remains largely unknown. Up-regulation of RNase L in
lung cancer cells may  be due to such a feedback response. The
growing-regulatory machinery in the cells attempt to counter-
act the proliferative effect by promoting RNase L expression. On
the other hand, the suppressive machinery overproduces RLI to
inhibit the activity of RNase L. As a result, both RNase L and
RLI are highly expressed in lung cancer cells. The unique regu-
latory mode may  provide a special strategy to treat lung cancer
by promoting the activity of RNase L through suppression of
RLI.
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